XASXAT1
Market cap7mUSD
Jan 02, Last price
0.02AUD
1D
0.00%
1Q
-9.52%
IPO
-96.35%
Name
Atomo Diagnostics Ltd
Chart & Performance
P/E
—
P/S
2.97
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.50%
Rev. gr., 5y
49.91%
Revenues
4m
+60.65%
Net income
-7m
L-31.23%
CFO
-5m
L-19.86%
Earnings
Feb 24, 2025
Profile
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. It offers rapid diagnostic test devices for COVID-19, HIV screening, pregnancy test, and respiratory test. The company was incorporated in 2010 and is headquartered in Leichhardt, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||
Revenues | 4,087 60.65% | 2,544 -79.38% | 12,336 83.69% | |||||
Cost of revenue | 6,942 | 12,583 | 20,443 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (2,856) | (10,039) | (8,107) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (946) | (1,029) | ||||||
Tax Rate | ||||||||
NOPAT | (2,856) | (9,093) | (7,078) | |||||
Net income | (6,848) -31.23% | (9,958) 74.49% | (5,707) -5.22% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 2,050 | 68 | ||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 85 | 171 | 156 | |||||
Long-term debt | 85 | 168 | 370 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 107 | 105 | 93 | |||||
Net debt | (3,519) | (6,131) | (12,441) | |||||
| Cash flow | ||||||||
Cash from operating activities | (4,686) | (5,848) | (2,807) | |||||
CAPEX | (16) | (401) | (2,306) | |||||
Cash from investing activities | (16) | (401) | (2,306) | |||||
Cash from financing activities | 1,867 | (171) | 18 | |||||
FCF | (1,992) | (4,007) | (5,683) | |||||
| Balance | ||||||||
Cash | 3,688 | 6,470 | 12,966 | |||||
Long term investments | ||||||||
Excess cash | 3,484 | 6,343 | 12,350 | |||||
Stockholders' equity | 10,085 | 14,790 | 24,814 | |||||
Invested Capital | 6,792 | 8,807 | 12,898 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 634,659 | 570,891 | 568,950 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (1,196) | (8,147) | (6,110) | |||||
EV/EBITDA | ||||||||
Interest | 10 | 15 | 15 | |||||
Interest/NOPBT | ||||||||